Kuangxiong Aerosol

Phase 3Small molecule

CChina-Japan Friendship Hospital

Kuangxiong Aerosol is one of 26 small molecule programs targeting Vascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vascular DiseaseNot yet recruiting

Vascular DiseasePhase 3

Not yet recruiting

Competition

Competitive Landscape

26 competitors in Vascular Disease

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

2 2

Repatha

Amgen

Approved

1 3

Precose

Bayer

Approved

1 4

Colcrys

Letairis

Xarelto

1 7

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 8

Andriol

AAuxilium

Approved

1 9

Aricept

Eisai

Approved

2 10

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Post-ApprovalNot yet recruiting

Vascular Disease

NCT06901570

Clinical

Trials by Indication[1]

Vascular Disease1 trial

Clinical Evaluation of Aromatic Wentong in the Treatment of Coronary Microvascular Disease

Not yet recruiting·—·Phase 4·NCT06901570·528 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Kuangxiong Aerosol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kuangxiong Aerosol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kuangxiong Aerosol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — China-Japan Friendship Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChina-Japan Friendship Hospital

Kuangxiong Aerosol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Vascular Disease1 trial

References

Drug Info

Quick Facts

Related News